Ultragenyx Pharmaceutical/$RARE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Ticker
$RARE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,294
ISIN
US90400D1081
Website
RARE Metrics
BasicAdvanced
$2.9B
-
-$5.88
0.24
-
Price and volume
Market cap
$2.9B
Beta
0.24
52-week high
$58.73
52-week low
$29.06
Average daily volume
1.6M
Financial strength
Current ratio
2.397
Quick ratio
2.048
Long term debt to equity
543.374
Total debt to equity
346.939
Interest coverage (TTM)
-8.35%
Profitability
EBITDA (TTM)
-477.877
Gross margin (TTM)
-30.87%
Net profit margin (TTM)
-93.04%
Operating margin (TTM)
-86.94%
Effective tax rate (TTM)
-0.45%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-24.51%
Return on equity (TTM)
-377.06%
Valuation
Price to revenue (TTM)
4.915
Price to book
20.17
Price to tangible book (TTM)
-37.94
Price to free cash flow (TTM)
-7.028
Free cash flow yield (TTM)
-14.23%
Free cash flow per share (TTM)
-441.57%
Growth
Revenue change (TTM)
33.46%
Earnings per share change (TTM)
-26.22%
3-year revenue growth (CAGR)
21.18%
3-year earnings per share growth (CAGR)
-5.10%
10-year earnings per share growth (CAGR)
10.73%
What the Analysts think about RARE
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
Bulls say / Bears say
Ultragenyx received Breakthrough Therapy Designation from the FDA for GTX-102 (apazunersen) as a treatment for Angelman syndrome, potentially expediting its development and review process. (angelman.org)
The company reported a 29% increase in total revenue for 2024, reaching $560 million, surpassing its own guidance and indicating robust financial performance. (tipranks.com)
Ultragenyx's international expansion, including the launch of EVKEEZA in Europe, Canada, and Japan, led to a 78% growth in CRYSVITA sales in Latin America and Turkey compared to 2023. (tipranks.com)
Despite revenue growth, Ultragenyx reported a net loss of $569 million for 2024, translating to a loss of $6.29 per share, highlighting ongoing financial challenges. (tipranks.com)
Operating expenses for 2024 amounted to $1.1 billion, with significant investments in R&D and SG&A, indicating high costs that may impact profitability. (tipranks.com)
Ultragenyx's net cash used in operations totaled $414 million in 2024, reflecting a high cash burn rate that could pose risks if not managed effectively. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RARE Financial Performance
Revenues and expenses
RARE Earnings Performance
Company profitability
RARE News
AllArticlesVideos
Ultragenyx shares plunge after bone disorder trial misses key interim goal
Proactive Investors·20 hours ago
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
Benzinga·1 day ago
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical (RARE) has a market cap of $2.9B as of July 11, 2025.
What is the P/E ratio for Ultragenyx Pharmaceutical stock?
The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of July 11, 2025.
Does Ultragenyx Pharmaceutical stock pay dividends?
No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Ultragenyx Pharmaceutical dividend payment date?
Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.